# Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects

> **NCT01865552** · PHASE1 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 138 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** SB4
- **BIOLOGICAL:** EU sourced Enbrel
- **BIOLOGICAL:** US sourced Enbrel

## Key facts

- **NCT ID:** NCT01865552
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01865552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01865552, "Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01865552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*